| Reporting Organization: | UNOPS - United Nations Office for Project Services |
|---|---|
| Total Budget ($CAD): | $ 37,121,095 |
| Timeframe: | March 20, 2010 - February 11, 2020 |
| Status: | Completion |
| Contact Information: | Unspecified |
UNOPS - United Nations Office for Project Services
Unspecified
| Sub-Saharan Africa - $ 11,433,297.26 (30.80%) | |
|
|
|
| Southeast Asia - $ 7,535,582.29 (20.30%) | |
|
|
|
| South Asia - $ 6,162,101.77 (16.60%) | |
|
|
|
| East Asia - $ 5,531,043.16 (14.90%) | |
|
|
|
| Central Asia - $ 3,415,140.74 (9.20%) | |
|
|
|
| North Africa - $ 1,559,085.99 (4.20%) | |
|
|
|
| Europe - $ 1,113,632.85 (3.00%) | |
|
|
|
| South America - $ 259,847.67 (0.70%) | |
|
|
|
| Central America - $ 111,363.29 (0.30%) | |
|
|
|
| Infectious & Communicable Diseases (100 %) | |
|
|
|
This grant represents part of Canada’s contribution to the Global Drug Facility (GDF), a program of the Stop TB Partnership. It provides access to anti-tuberculosis (TB) drugs for governments that agree to introduce, expand, or maintain the diagnostic, treatment, and monitoring policies of the DOTS (directly observed treatment, short-term) strategy. Launched in 2001, the GDF works to improve the supply, distribution, and monitoring of anti-TB drugs in developing countries and is the only global bulk procurer of anti-TB drugs. Canada was the founding donor of the GDF and to date (2010) has been the single largest donor country for first-line TB drugs. The GDF is a four-pronged mechanism whereby: (1) countries who cannot afford to procure all the anti-TB drug they need are eligible to apply for drugs for up to six years (DFATD provides funding for this component); (2) countries who can pay for the anti-TB drugs they need but cannot assure the quality of the drugs can directly procure them through the GDF at reduced bulk prices (DFATD funding does not contribute to this component); (3) countries where the procurement system is weak can receive technical assistance to strengthen their capacity for drug procurement (DFATD supports this component); and (4) Global Fund recipient countries can procure anti-TB drugs directly through GDF, using Global Fund monies, to ensure a stable and high-quality drug supply.
| Gender and age: | Adult women Adult men Adolescent females Adolescent males Children, girls Children, boys Under-5 children Newborns Older adults, women Older adults, men |
|---|---|
| Total Direct Population: | Unspecified |
Unspecified
Return to topUnspecified
Results achieved by Global Drug Facility, through the support of the Government of Canada and other international donors, as of March 2016 include: (1) provided quality-assured treatments since 2001 for more than 27 million patients with tuberculosis (TB), This included over 184,000 patient treatments for multi-drug resistant TB (MDR-TB) and 1.5 million treatments for children; (2) delivered over 1.5 million patient treatments, including over 219,000 pediatric treatments in 2015; (3) provided capacity-building support to 134 countries since 2001, including training and workshops, monitoring missions and technical assistance to improve the management of drug supplies; (4) contributed to planning and guidance for the global introduction of new child-friendly medicines for pediatric TB; and (5) provided a mechanism for countries to order the new pediatric formulations and made grants available to eligible countries to purchase pediatric TB medicines with funding from Global Affairs Canada.
